Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Breast cancer

S100 calcium binding protein A14 (S100A14); HER2 (EGFR2; ErbB2; neu)

In vitro studies suggest inhibiting S100A14 could help treat HER2+ breast cancer. In primary HER2+ breast tumors, S100A14 levels were higher than those in surrounding normal tissue and correlated with poor prognosis. In HER2+ human breast cancer cell lines, siRNA against S100A14 decreased HER2 activation and subsequent cell growth compared with a scrambled siRNA. Planned work includes testing S100A14 knockdown in animals with HER2+ xenograft breast tumors.

SciBX 7(2); doi:10.1038/scibx.2014.47
Published online Jan. 16, 2014

Unpatented; unlicensed; available for partnering

Xu, C. et al. J. Biol. Chem.; published online Nov. 27, 2013;
doi:10.1074/jbc.M113.469718
Contact: Zhihua Liu, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
e-mail:
liuzh@cicams.ac.cn

Contact: Hongyan Chen, same affiliation as above
e-mail:
chenhongyan@cicams.ac.cn